Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Fedor V. Moiseyenko"'
Autor:
Anna P. Sokolenko, Fedor V. Moiseyenko, Aglaya G. Iyevleva, Alexandr O. Ivantsov, Georgiy D. Dolmatov, Ksenia V. Shelekhova, Elizaveta V. Gulo, Anastasya X. Topal, Elizaveta V. Artemieva, Nuriniso H. Abduloeva, Nikita A. Rysev, Daria A. Barsova, Natalia V. Levchenko, Nikita M. Volkov, Vitaliy V. Egorenkov, Vladimir M. Moiseyenko, Evgeny N. Imyanitov
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 3, p 1870 (2023)
Neoadjuvant chemotherapy (NACT) for breast cancer (BC) often results in pathologic complete response (pCR), i.e., the complete elimination of visible cancer cells. It is unclear whether the use of ultrasensitive genetic methods may still detect resid
Externí odkaz:
https://doaj.org/article/d29bcd9543e14487a81b90919bd08a04
Autor:
Fedor V. Moiseyenko, Vitaliy V. Egorenkov, Mikhail M. Kramchaninov, Elizaveta V. Artemieva, Svetlana N. Aleksakhina, Maxim M. Holmatov, Vladimir M. Moiseyenko, Evgeny N. Imyanitov
Publikováno v:
Case Reports in Oncology, Vol 12, Iss 2, Pp 339-343 (2019)
Vemurafenib has been developed to target common BRAF mutation V600E. It also exerts activity towards some but not all rare BRAF substitutions. Proper cataloguing of drug-sensitive and -insensitive rare mutations remains a challenge, due to low occurr
Externí odkaz:
https://doaj.org/article/f3fe4fb603f74a8c8c7e0175c35ce4aa
Autor:
Fedor V. Moiseyenko, Ekaterina S. Kuligina, Albina S. Zhabina, Sergey A. Belukhin, Tatiana A. Laidus, Aleksandr S. Martianov, Kirill A. Zagorodnev, Tatyana N. Sokolova, Svetlana A. Chuinyshena, Maxim M. Kholmatov, Elizaveta V. Artemieva, Ekaterina O. Stepanova, Tatiana N. Shuginova, Nikita M. Volkov, Grigoriy A. Yanus, Evgeny N. Imyanitov
Publikováno v:
International Journal of Clinical Oncology. 27:850-862
This study aimed to analyze changes in the plasma concentration of EGFR-mutated circulating tumor DNA (ctDNA) occurring immediately after the start of therapy with EGFR tyrosine kinase inhibitors (TKIs).Serial plasma samples were collected from 30 pa
Autor:
Nina Karaseva, Vladimir M. Moiseyenko, Ivan S. Sardaryan, Maxim M. Kholmatov, Svetlana V. Odintsova, Nikita M. Volkov, Elena A. Filippova, Natalia V. Mitiushkina, Alexandra M. Lozhkina, Fedor V. Moiseyenko, Vladislav I. Tiurin, Sergey Orlov, Nikita Levchenko, Evgeny N. Imyanitov, Aglaya G. Iyevleva
Publikováno v:
Biochimie. 154:19-24
Multiple laboratory evidences indicate that distinct variants of ALK translocations differ in their biochemical properties and responsiveness to ALK tyrosine kinase inhibitors (TKIs). These data are supported by some clinical studies, which showed im
Autor:
Tatyana N. Sokolova, Fedor V. Moiseyenko, Alexey A Kudriavtsev, Aglaya G. Iyevleva, Natalia V. Mitiushkina, Mikhail M Kramchaninov, Alexandr O. Ivantsov, Svetlana N. Aleksakhina, Grigoriy A. Yanus, Nikita M. Volkov, Elena V. Preobrazhenskaya, Kseniya S. Kozyreva, Kseniya V. Shelekhova, Ilya V. Bizin, Alexandr S. Zhuravlev, Ekatherina Sh. Kuligina, Aigul R. Venina, Evgeny N. Imyanitov, Denis V Pashkov, Anna P. Sokolenko, Vyacheslav A. Chubenko, Vladimir M. Moiseyenko, Alexandr V. Togo
Publikováno v:
Clinical Drug Investigation. 38:553-562
Colorectal carcinomas (CRCs) are sensitive to treatment by anti-epidermal growth factor receptor (EGFR) antibodies only if they do not carry activating mutations in down-stream EGFR targets (KRAS/NRAS/BRAF). Most clinical trials for chemo-naive CRC p
Autor:
Elena D Lavdovskaia, Ilya V. Bizin, Nina Karaseva, I. Chistyakov, Fedor V. Moiseyenko, Ivan A Zaitsev, Anna P. Sokolenko, Andrey Akopov, Vladislav I. Tiurin, Andrey R Kozak, Natalia V. Mitiushkina, Alexandr V. Togo, Evgeny N. Imyanitov, Vladimir M. Moiseyenko, Sergey Orlov, Nikita M. Volkov, Marina A Korzhenevskaya, Liliya V Stelmakh, Alexandr O. Ivantsov, Elena V. Preobrazhenskaya, Aglaya G. Iyevleva
Publikováno v:
Oncology Research and Treatment. 41:634-642
Background: This study evaluated the distribution of epidermal growth factor receptor (EGFR) T790M mutations in treatment-naïve tumor and normal samples obtained from cancer patients. Methods: We utilized allele-specific PCR (AS-PCR), digital drople
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(16)
Metastatic non–small-cell lung cancer is still a devastating disease; however, treatment options have diversified dramatically in the past two decades. From unselected platinum-based chemotherapy for all patients, several different treatment groups
Autor:
Nikita M. Volkov, Kseniya V. Shelekhova, Alexandr O. Ivantsov, Elena V. Preobrazhenskaya, Michail M. Kramchaninov, Fedor V. Moiseyenko, Kseniya S. Kozyreva, Svetlana N. Aleksakhina, Aigul R. Venina, Natalia V. Mitiushkina, Aglaya G. Iyevleva, Vyacheslav A. Chubenko, Alexandr S. Zhuravlev, Evgeny N. Imyanitov, Vladimir M. Moiseyenko
Publikováno v:
Oncology Research and Treatment. 39:605-614
Background: Discontinuation of gefitinib treatment is often accompanied by a disease flare. Some studies have demonstrated a benefit of the use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) beyond progression; however, l
Autor:
Anna P. Sokolenko, Vladimir M. Moiseyenko, Evgeny N. Imyanitov, Valeriya I. Ni, Nataliya E Gesha, Elena V. Preobrazhenskaya, Lyudmila A Zagorskaya, Yuliya A Zaytseva, Vyacheslav A. Chubenko, Fedor V. Moiseyenko, Evgeny N Zykov
Publikováno v:
Cureus
This report describes an estrogen receptor-positive breast cancer patient, who relapsed at two and a half years after the completion of adjuvant chemotherapy while being on the aromatase inhibition. Based on the clinical evidence for potential sensit
Autor:
Alexandr O. Ivantsov, Vladimir M. Moiseyenko, Nikita M. Volkov, Vyacheslav A. Chubenko, Fedor V. Moiseyenko, Georgiy D. Dolmatov, A. A. Bogdanov, Evgeny N. Imyanitov, Nuriniso Kh. Abduloeva, Anna P. Sokolenko
Publikováno v:
Medical Oncology. 32
Development of malignancies in BRCA1 germ-line mutation carriers usually involves somatic inactivation of the remaining BRCA1 allele. This feature leads to a tumor-specific deficiency of double-strand DNA break repair and underlies pronounced sensiti